Amir Avan
Impact in
- Oncology top 5%
- Pancreatic and Hepatic Oncology Research
- Cancer Treatment and Pharmacology
- Cancer Cells and Metastasis
- Cancer Research top 10%
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
Papers in
- Oncology 13
- Pancreatic and Hepatic Oncology Research 9
- Colorectal Cancer Treatments and Studies 4
- Cancer Cells and Metastasis 2
- HER2/EGFR in Cancer Research 2
-
- Renal and related cancers 3
- RNA modifications and cancer 2
- Co-authors
- Elisa Giovannetti (20 shared papers)Godefridus J. Peters (19 shared papers)Niccola Funel (15 shared papers)Mina Maftouh (10 shared papers)Abolfazl Avan (4 shared papers)Tjeerd J. Postma (1 shared paper)Guido Cavaletti (1 shared paper)C Ceresa (1 shared paper)
- Journals
- Current Pharmaceutical Design (3 papers)Current Drug Targets (3 papers)PLoS ONE (2 papers)Scientific Reports (1 paper)Journal of Hematology & Oncology (1 paper)
- Partner nations
- NetherlandsItalyIran
In The Last Decade
Amir Avan
23 papers receiving 973 citations
Peers
Comparison fields: 5 of 73
- Oncology 441
- Cancer Research 211
- Hepatology 67
- Molecular Biology 416
- Immunology 75
Countries citing papers authored by Amir Avan
This map shows the geographic impact of Amir Avan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amir Avan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amir Avan more than expected).
Fields of papers citing papers by Amir Avan
This network shows the impact of papers produced by Amir Avan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amir Avan. The network helps show where Amir Avan may publish in the future.
Co-authors
The 25 scholars most cited alongside Amir Avan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 24 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2015 | 187 | |
| 2 | 2012 | 80 | |
| 3 | 2013 | 72 | |
| 4 | 2017 | 72 | |
| 5 | 2017 | 69 | |
| 6 | 2019 | 65 | |
| 7 | 2012 | 56 | |
| 8 | 2014 | 53 | |
| 9 | 2012 | 53 | |
| 10 | 2014 | 50 | |
| 11 | 2013 | 50 | |
| 12 | 2014 | 49 | |
| 13 | 2014 | 36 | |
| 14 | 2013 | 24 | |
| 15 | Predictive role of repair enzymes in the efficacy of Cisplatin combinations in pancreatic and lung cancer. | 2014 | 21 |
| 16 | 2014 | 16 | |
| 17 | 2013 | 10 | |
| 18 | 2014 | 6 | |
| 19 | 2014 | 6 | |
| 20 | 2012 | 3 |
About Amir Avan
Amir Avan is a scholar working on Oncology, Molecular Biology, Cancer Research, Hepatology and Pathology and Forensic Medicine, having authored 24 papers that have together received 983 indexed citations. Recurring topics across this work include Pancreatic and Hepatic Oncology Research (9 papers), Liver physiology and pathology (4 papers), Colorectal Cancer Treatments and Studies (4 papers), Renal and related cancers (3 papers), MicroRNA in disease regulation (3 papers), Cancer Cells and Metastasis (2 papers), HER2/EGFR in Cancer Research (2 papers) and RNA modifications and cancer (2 papers). The work is most often cited by research in Oncology (441 citations), Cancer Research (211 citations), Hepatology (67 citations), Molecular Biology (416 citations) and Immunology (75 citations). Amir Avan has collaborated with scholars based in Netherlands, Italy and Iran. Frequent co-authors include Elisa Giovannetti, Godefridus J. Peters, Niccola Funel, Mina Maftouh, Abolfazl Avan, Tjeerd J. Postma, Guido Cavaletti, C Ceresa, Ugo Boggi and Leticia G. León. Their work appears in journals such as Current Pharmaceutical Design, Current Drug Targets, PLoS ONE, Scientific Reports and Journal of Hematology & Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.